Back to Search
WILLIAM SHIPLEY, MD
MD
Anatomic Pathology & Clinical Pathology Physician
NPI: 1821038811IndividualAccepts Medicare
Specialties, Licenses & Credentials
Anatomic Pathology & Clinical Pathology PhysicianPrimary
Pathology — Anatomic Pathology & Clinical Pathology
Code: 207ZP0102X
89030(SC)99-00348(NC)
CMS Specialties
PrimaryPATHOLOGY
Education
MEDICAL UNIVERSITY OF SOUTH CAROLINA COLLEGE OF MEDICINE
Class of 1994
Research & Publications (20)
Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.
PMID 16427211·Int J Radiat Oncol Biol Phys·2006
2-rct
Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences.
PMID 15662605·Semin Radiat Oncol·2005
6-review
Overview of bladder cancer trials in the Radiation Therapy Oncology Group.
PMID 12673704·Cancer·2003
6-review
Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer.
PMID 12100923·Urology·2002
8-other
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.
PMID 19047297·J Clin Oncol·2009
3-trial
Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.
PMID 19636019·J Clin Oncol·2009
3-trial
The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
PMID 19154448·BJU Int·2009
8-other
Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.
PMID 19211454·J Natl Cancer Inst·2009
3-trial
Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
PMID 19100600·Urology·2009
3-trial
Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer.
PMID 18947941·Int J Radiat Oncol Biol Phys·2009
4-observational
Surgery: selective bladder-preserving therapy for muscle-invasive cancer.
PMID 19333224·Nat Rev Clin Oncol·2009
8-other
Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610.
PMID 18977097·Int J Radiat Oncol Biol Phys·2009
8-other
Bladder preservation: optimizing radiotherapy and integrated treatment strategies.
PMID 19035903·BJU Int·2008
6-review
Newer imaging modalities to assist with target localization in the radiation treatment of prostate cancer and possible lymph node metastases.
PMID 18406936·Int J Radiat Oncol Biol Phys·2008
6-review
Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.
PMID 18413638·J Clin Oncol·2008
3-trial
Celebrating 40 years of clinical inquiry: The RTOG'S ruby anniversary.
PMID 18474307·Int J Radiat Oncol Biol Phys·2008
8-other
Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02.
PMID 18779620·J Clin Oncol·2008
2-rct
Structure and functional role of dynein's microtubule-binding domain.
PMID 19074350·Science·2008
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 201 E GROVER ST
SHELBY, NC 28150 - Phone
- (980) 487-3147
Quick Facts
- NPI
- 1821038811
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 32
- Publications
- 20
Are you this provider?
Claim Your Profile